Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-1
- Development stage
- Unknown
- Lead developer
- CBA Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CBT-1 is an orally bioavailable small molecule bisbenzylisoquinoline alkaloid, specifically a purified form of d-tetrandrine, that acts as a potent inhibitor of the P-glycoprotein (P-gp) efflux pump. P-gp, encoded by the ABCB1 (MDR1) gene, is an ATP-binding cassette transporter that frequently mediates multidrug resistance in cancer by actively extruding various chemotherapeutic agents from tumor cells. CBT-1 is designed to be administered in combination with cytotoxic drugs, such as paclitaxel or doxorubicin, to enhance their intracellular accumulation and therapeutic efficacy. Developed in collaboration with the National Cancer Institute (NCI), CBT-1 has been evaluated in clinical trials for the treatment of relapsed or refractory solid tumors and anthracycline-refractory sarcomas. It has demonstrated the ability to inhibit P-gp-mediated drug efflux in both tumor and normal tissues without significantly altering the systemic pharmacokinetics of co-administered chemotherapy.
- Brand names
- CBT-1CBT1CBT 1
- Other names
- Tetrandrined-tetrandrine
02
Targets
ABCC1 (MRP1)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on CBT-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-1.